Brainstorm Cell Therapeutics Inc. (BCLI)
Chart Events
Performance Outlook
| Previous Close | 2.9100 |
| Open | 2.9000 |
| Bid | 2.9400 x 800 |
| Ask | 3.0000 x 800 |
| Day's Range | 2.8800 - 3.0000 |
| 52 Week Range | 2.5200 - 4.4600 |
| Volume | |
| Avg. Volume | 55,906 |
| Market Cap | 107.02M |
| Beta (5Y Monthly) | 0.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8510 |
| Earnings Date | Apr 25, 2022 - Apr 29, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
BrainStorm to Announce Second Quarter Results and Provide a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on financial results for the second quarter, ended on June 30, 2022, and provide a corporate update, at 8:00 a.m. Eastern Time on Monday, August 15, 2022.
- PR Newswire
BrainStorm Announces Presentations at June 2022 Scientific Conferences
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announces presentations at forthcoming ALS and MS scientific conferences in June 2022. Insights into the ALS Phase 3 primary endpoint leveraging ENCALS model patient prognosis trajectories will be presented as a scientific poster at the European Network to Cure ALS (ENCALS) meeting in Edinburgh, Scotland June 1-3, 2022. At the Consortium of Multiple Sclerosis Centers
- Zacks Small Cap Research
BCLI: Anticipating News on How NurOwn® Will be Advanced Forward…
By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Anticipating News on How NurOwn® Will be Advanced Forward in ALS BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is developing NurOwn as a treatment for patients with amyotrophic lateral sclerosis (ALS). The company recently published results from the Phase 3 trial of NurOwn in Muscle and Nerve that showed while
